{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T12:19:04Z","timestamp":1783167544461,"version":"3.54.6"},"reference-count":10,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leptomeningeal disease is a complication of advanced solid tumors, and treatment options are limited by inadequate central nervous system penetration. Intrathecal pemetrexed has emerged as an off-label therapeutic option. However, data describing its hematologic toxicity, particularly neutropenia, are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the incidence, timing, and severity of neutropenia associated with intrathecal pemetrexed and to assess differences in neutropenia risk among clinically relevant subgroups, such as concomitant osimertinib use, vitamin supplementation, and exposure to other bone marrow suppressing medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was conducted of adult patients who received at least one dose of intrathecal pemetrexed over a four-year period. Patient demographics, treatment characteristics, laboratory values, concomitant therapies, and history of prior craniospinal irradiation were extracted from the electronic health record. The primary outcome was incidence of neutropenia, defined as an absolute neutrophil count &lt;1.0\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Exploratory subgroup analyses evaluated neutropenia incidence and severity based on concomitant osimertinib therapy, vitamin supplementation status, and use of other medications with bone marrow suppressing potential.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixteen patients who received 138 doses were included. Neutropenia occurred in approximately one-third of patients, most commonly after loading doses. Higher neutropenia incidence and earlier onset were observed in patients receiving concomitant osimertinib and those not receiving vitamin B12 and folic acid supplementation. No consistent increase in neutropenia was observed with other marrow-suppressing medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intrathecal pemetrexed is associated with clinically meaningful neutropenia. Subgroup findings highlight the importance of vitamin supplementation, careful regimen assessment, and close hematologic monitoring to optimize safety and patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552261460354","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:31:15Z","timestamp":1782844275000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence of neutropenia with intrathecal pemetrexed for leptomeningeal disease associated with solid tumors \u2013 A retrospective analysis"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7983-5653","authenticated-orcid":false,"given":"Nicholas D","family":"Ngo","sequence":"first","affiliation":[{"name":"UC San Diego Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshika","family":"Singh","sequence":"additional","affiliation":[{"name":"UC San Diego Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Hampton","sequence":"additional","affiliation":[{"name":"UC San Diego Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E","family":"Piccioni","sequence":"additional","affiliation":[{"name":"UC San Diego Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip P","family":"Patel","sequence":"additional","affiliation":[{"name":"UC San Diego Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 2.2025. National Comprehensive Cancer Network Inc 2025"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102384"},{"key":"e_1_3_3_4_2","unstructured":"Eli Lilly and Company: Pemetrexed (Alimta) prescribing information. Eli Lilly and Company Indianapolis IN 2004"},{"key":"e_1_3_3_5_2","unstructured":"AstraZeneca Pharmaceuticals LP: Osimertinib (Tagrisso) prescribing information. AstraZeneca Pharmaceuticals LP Wilmington DE 2024"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.018"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00838"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.11.011"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1792"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1543416"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.32604\/or.2025.064237"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261460354","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552261460354","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552261460354","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:49:21Z","timestamp":1783165761000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552261460354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":10,"alternative-id":["10.1177\/10781552261460354"],"URL":"https:\/\/doi.org\/10.1177\/10781552261460354","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"10781552261460354"}}